CD274 and neoplasm: Yet, so far, only tumour tissue-based markers, such as PD-L1, tumour mutational burden (TMB-H) and mismatch repair deficiency/microsatellite instability (dMMR/MSI-H), are approved biomarkers for administration of immunotherapy (Food and Drug Administration 2017a, b, 2020, 2021).